Asston Pharmaceu

Why is Asston Pharmaceuticals Ltd falling/rising?

As of 01-Sep, Asston Pharmaceuticals Ltd's stock price has fallen to Rs. 113.40, reflecting an 8.94% decrease after four days of gains, indicating a trend reversal and high volatility. Despite strong long-term performance, the current decline suggests a shift in market sentiment and a lack of buying support at higher levels.

As of 01-Sep, Asston Pharmaceuticals Ltd's stock price is falling, currently at Rs. 113.40, which reflects a decrease of Rs. 11.14 or 8.94%. This decline comes after a period of four consecutive days of gains, indicating a trend reversal. The stock has underperformed its sector by 8.67% today and has experienced high volatility, with an intraday volatility of 5.88%. Additionally, the stock touched an intraday low of Rs. 112.1, marking a significant drop of 9.99%. <BR><BR>Despite the recent decline, the stock has shown strong performance over longer periods, with a 1-week increase of 37.69% and a 1-month increase of 69.25%. However, the current day's performance suggests a shift in market sentiment, as the stock is trading lower than its new 52-week high of Rs. 126.1 reached earlier today. The weighted average price indicates that more volume was traded closer to the low price, which could signal a lack of buying support at higher levels. Overall, the combination of recent price action, high volatility, and underperformance relative to the sector contributes to the current decline in Asston Pharmaceuticals Ltd's stock price.

What does Asston Pharmaceu do?

Asston Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 104 Cr. It currently has no reported net sales or profits, a P/E ratio of 27.00, and a debt-equity ratio of 0.10.

Overview: <BR>Asston Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Details regarding the incorporation year and any status changes are not available. Additionally, there are no sales and profit reports for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 104 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.10 <BR>Return on Equity: 10.02% <BR>Price-to-Book: 2.56 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Asston Pharmaceu?

Asston Pharmaceu's peers include Veerhealth Care, Denis Chem Lab, Mercury Labs, Amwill Health, Sunil Healthcare, Vineet Laborator, Samrat Pharma, Onyx Biotec, and Sotac Pharma. Notably, Veerhealth Care has the highest 1-year return at 157.30%, while Denis Chem Lab has the lowest at -24.43%.

Peers: The peers of Asston Pharmaceu are Veerhealth Care, Denis Chem Lab, Mercury Labs, Amwill Health, Sunil Healthcare, Vineet Laborator, Samrat Pharma, Onyx Biotec, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health, while Good management risk is found at Denis Chem Lab, and the rest have Average or Below Average management risk. Good growth is seen at Veerhealth Care and Sunil Healthcare, while Average growth is noted at Amwill Health, and the rest have Below Average growth. Excellent capital structure is present at Denis Chem Lab and Amwill Health, while Average capital structure is found at Asston Pharmaceu, Onyx Biotec, and Sotac Pharma, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Veerhealth Care has the highest 1-year return at 157.30%, while Denis Chem Lab has the lowest at -24.43%, with Asston Pharmaceu's 1-year return at 25.54%, which is positive compared to Denis Chem Lab. Additionally, Mercury Labs, Amwill Health, and Samrat Pharma have negative six-month returns.

How big is Asston Pharmaceu?

As of 31st August, Asston Pharmaceuticals Ltd has a market capitalization of 104.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Asston Pharmaceuticals Ltd has a market capitalization of 104.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2025, with Shareholder's Funds reported at 11.04 Cr and Total Assets at 28.10 Cr.

Which are the latest news on Asston Pharmaceu?

When is the next results date for Asston Pharmaceuticals Ltd?

The next results date for Asston Pharmaceuticals Ltd is 29 May 2026.

The next results date for Asston Pharmaceuticals Ltd is scheduled for 29 May 2026.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.